STOCK TITAN

Alzamend Neuro, Inc. (ALZN) Debt by Year

ALZN

Alzamend Neuro, Inc. held $711K in cash and equivalents at the end of fiscal year 2026, and long-term debt is not reported for that period. The table below carries 7 fiscal years, from 2020 to 2026, and the quarters Alzamend Neuro, Inc. has filed alongside them.

FY2026 annual
Long-Term Debt N/A
Cash & Equivalents $711K
Source SEC Filings (10-K/10-Q) Latest period Q1 FY2027, ended Jul 31, 2026 Reported Currency USD

Annual figures, oldest first. Point at a bar to read its period.

ALZN Debt & Cash by Fiscal Year

Figures are as reported in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.

MetricFY2610-KFY2510-KFY2410-KFY2310-KFY2210-KFY2110-KFY2010-K
Long-Term DebtN/AN/AN/AN/AN/AN/AN/A
Cash & Equivalents$711K-82.0%$3.9M+950.0%$376K-92.7%$5.1M-63.4%$14.1M+629.0%$1.9M+2036.9%$90K

ALZN Debt & Cash by Quarter

Figures are as reported in USD. Each change compares the quarter with the same quarter a year earlier.

MetricQ1'2710-QQ4'2610-QQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-KQ3'2410-QQ2'2410-Q
Long-Term DebtN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Cash & Equivalents$7.6M+35.1%$711K-82.0%$2.7M-19.2%$4.4M+8.7%$5.6M+370.8%$3.9M+950.0%$3.4M+1087.2%$4.1M+1945.7%$1.2M-29.6%$376K-92.7%$283K-96.2%$200K-97.8%

What long-term debt means

Long-term debt is borrowing that falls due more than a year out, and the cash line beside it is what the company held on the same balance sheet date.

More Alzamend Neuro, Inc. financials

Frequently Asked Questions

What was Alzamend Neuro, Inc.'s long-term debt in fiscal year 2026?

Alzamend Neuro, Inc. held $711K in cash and equivalents at the end of fiscal year 2026, and long-term debt is not reported for that period.

What does long-term debt mean on a financial statement?

Long-term debt is borrowing that falls due more than a year out, and the cash line beside it is what the company held on the same balance sheet date. This page lists what Alzamend Neuro, Inc. (ALZN) reported on that line in every period on record.